Desmopressin for nocturnal enuresis in nephrogenic diabetes insipidus.
We have investigated two unrelated families, in which two children had inherited primary nocturnal enuresis, and nephrogenic diabetes insipidus caused by new mutations in the aquaporin-2 gene (AQP2). The mutant AQP2 proteins were inactive, suggesting that administration of desmopressin could not concentrate the urine in these patients. However, treatment with desmopressin resolved primary nocturnal enuresis completely. This observation questions the notion that desmopressin resolves primary nocturnal enuresis through pharmacological manipulation of renal concentrating ability only. Desmopressin might also act on extrarenal targets such as the central nervous system.
Müller
Dominik
D
Marr
Nannette
N
Ankermann
Tobias
T
Eggert
Paul
P
Deen
Peter M T
PM
D002648:Child; D003894:Deamino Arginine Vasopressin / Q000627:therapeutic use*; D018500:Diabetes Insipidus, Nephrogenic / Q000235:genetics*; D004775:Enuresis / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D010375:Pedigree; D012076:Renal Agents / Q000627:therapeutic use*
D012076:Renal Agents; D003894:Deamino Arginine Vasopressin